儿童多发性硬化初始疾病修饰治疗的真实世界疗效
这项队列研究纳入美国12家儿童MS中心的741例儿童MS/CIS患者,比较新型与注射型疾病修饰治疗(DMT)对疾病活动的影响。经倾向评分调整后,新型DMT组的复发率、新发/扩大T2病灶及钆增强病灶均显著低于注射型DMT组,支持新型治疗更有效。
要点
- 新型DMT组复发率显著低于注射型DMT组(率比0.45,95%CI 0.29-0.70)。
- 新型DMT组新发/扩大T2病灶风险显著更低(HR 0.51,95%CI 0.36-0.72)。
- 新型DMT组钆增强病灶风险显著更低(HR 0.38,95%CI 0.23-0.63)。
核心结论
- 儿童MS/CIS初始治疗使用新型DMT较注射型DMT能更好地控制疾病活动,支持新型治疗更有效。
研究设计与样本
- 队列研究,纳入美国12家儿童MS中心随访的儿童MS/CIS患者,共741例在18岁前开始治疗,其中197例使用新型DMT,544例使用注射型DMT。
主要发现
- 经倾向评分五分位调整后,新型DMT组复发率显著低于注射型DMT组(率比=0.45,95%CI=0.29-0.70,p<0.001;率差=0.27,95%CI=0.14-0.40,p=0.004)。
- 新型DMT组新发/扩大T2高信号病灶风险显著低于注射型DMT组(HR=0.51,95%CI=0.36-0.72,p<0.001)。
- 新型DMT组钆增强病灶风险显著低于注射型DMT组(HR=0.38,95%CI=0.23-0.63,p<0.001)。
- 需用新型而非注射型DMT治疗3.7人年以预防1次复发。
关键数值与推荐
- 新型DMT包括芬戈莫德、富马酸二甲酯、特立氟胺、那他珠单抗、利妥昔单抗、奥瑞珠单抗;注射型DMT包括干扰素-β、醋酸格拉替雷。
临床怎么用
- 对于儿童MS/CIS,初始治疗可优先考虑新型DMT以更好控制疾病活动,但需关注新型DMT的长期安全性数据。
局限性
- 新型DMT的长期安全性数据仍需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess real-world effectiveness of initial treatment with newer compared to injectable disease-modifying therapies (DMTs) on disease activity in pediatric multiple sclerosis (MS) and clinically isolated syndrome (CIS). METHODS: This is a cohort study of children with MS/CIS followed at 12 clinics in the US Network of Pediatric MS Centers, who received initial therapy with newer (fingolimod, dimethyl fumarate, teriflunomide, natalizumab, rituximab, ocrelizumab) or injectable (interferon-β, glatiramer acetate) DMTs. Propensity scores (PSs) were computed, including preidentified confounders. Relapse rate while on initial DMT was modeled with negative binomial regression, adjusted for PS-quintile. Time to new/enlarging T2-hyperintense and gadolinium-enhancing lesions on brain magnetic resonance imaging were modeled with midpoint survival analyses, adjusted for PS-quintile. RESULTS: A total of 741 children began therapy before 18 years, 197 with newer and 544 with injectable DMTs. Those started on newer DMTs were older (15.2 vs injectable 14.4 years, p = 0.001) and less likely to have a monofocal presentation. In PS-quintile-adjusted analysis, those on newer DMTs had a lower relapse rate than those on injectables (rate ratio = 0.45, 95% confidence interval (CI) = 0.29-0.70, p < 0.001; rate difference = 0.27, 95% CI = 0.14-0.40, p = 0.004). One would need to treat with newer rather than injectable DMTs for 3.7 person-years to prevent 1 relapse. Those started on newer DMTs had a lower rate of new/enlarging T2 (hazard ratio [HR] = 0.51, 95% CI = 0.36-0.72, p < 0.001) and gadolinium-enhancing lesions (HR = 0.38, 95% CI = 0.23-0.63, p < 0.001) than those on injectables. INTERPRETATION: Initial treatment of pediatric MS/CIS with newer DMTs led to better disease activity control compared to injectables, supporting greater effectiveness of newer therapies. Long-term safety data for newer DMTs are required. ANN NEUROL 2020 ANN NEUROL 2020;88:42-55.
引用
- Krysko KM, Graves JS, Rensel M, et al. Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis. Ann Neurol. 2020. PMID: 32267005. doi:10.1002/ana.25737
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。